PE20060366A1 - Derivados de aminopiridina como agonistas de dopamina - Google Patents

Derivados de aminopiridina como agonistas de dopamina

Info

Publication number: PE20060366A1
Authority: PE; Peru
Prior art keywords: alkyl; pyridin; amine; optionally substituted; dopamine agonists
Prior art date: 2004-05-27

Application number

PE2005000583A

Other languages

English (en)

Spanish (es)

Inventor

Andrew Simon Cook

David Hepworth

Charlotte Moira Norfor Allerton

Duncan Charles Miller

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-27

Filing date

2005-05-25

Publication date

2006-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060366(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-05-27 Priority claimed from GB0411891A external-priority patent/GB0411891D0/en

2004-06-03 Priority claimed from GB0412463A external-priority patent/GB0412463D0/en

2005-05-25 Application filed by Pfizer filed Critical Pfizer

2006-05-15 Publication of PE20060366A1 publication Critical patent/PE20060366A1/es

Links

150000003927 aminopyridines Chemical class 0.000 title abstract 2
229940052760 dopamine agonists Drugs 0.000 title 1
239000003136 dopamine receptor stimulating agent Substances 0.000 title 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 abstract 1
-1 3-PHENYLPROPYL Chemical class 0.000 abstract 1
206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229960003638 dopamine Drugs 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Gynecology & Obstetrics (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PE2005000583A 2004-05-27 2005-05-25 Derivados de aminopiridina como agonistas de dopamina PE20060366A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0411891A GB0411891D0 (en)	2004-05-27	2004-05-27	New aminopyridine derivatives and their use as pharmaceuticals
GB0412463A GB0412463D0 (en)	2004-06-03	2004-06-03	New aminopyridine derivatives and their use as pharmaceuticals

Publications (1)

Publication Number	Publication Date
PE20060366A1 true PE20060366A1 (es)	2006-05-15

Family

ID=34970000

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2005000583A PE20060366A1 (es)	2004-05-27	2005-05-25	Derivados de aminopiridina como agonistas de dopamina

Country Status (21)

Country	Link
EP (1)	EP1758862A1 (fr)
JP (1)	JP4198183B2 (fr)
AP (1)	AP2006003824A0 (fr)
AR (1)	AR049548A1 (fr)
AU (1)	AU2005247699A1 (fr)
BR (1)	BRPI0511571A (fr)
CA (1)	CA2567935C (fr)
EA (1)	EA200601982A1 (fr)
EC (1)	ECSP067029A (fr)
GT (1)	GT200500125A (fr)
IL (1)	IL179314A0 (fr)
MA (1)	MA28607B1 (fr)
MX (1)	MXPA06013786A (fr)
NL (1)	NL1029139C2 (fr)
NO (1)	NO20065326L (fr)
PA (1)	PA8635101A1 (fr)
PE (1)	PE20060366A1 (fr)
SV (1)	SV2005002129A (fr)
TW (1)	TW200609216A (fr)
UY (1)	UY28925A1 (fr)
WO (1)	WO2005115985A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0502509D0 (en) *	2005-02-07	2005-03-16	Pfizer Ltd	Novel salt form of a dopamine agonist
EA201101186A1 (ru)	2009-02-13	2012-04-30	Байер Фарма Акциенгезельшафт	Конденсированные пиримидины
EP2558437B1 (fr) *	2010-04-12	2015-08-05	Supernus Pharmaceuticals, Inc.	Procédés de fabrication de sels de viloxazine et leurs nouveaux polymorphes
WO2013003769A2 (fr)	2011-06-30	2013-01-03	Donaldson Company, Inc.	Ensembles séparateurs air/huile, composants et procédés
GB2543296A (en)	2015-10-13	2017-04-19	Indivior Uk Ltd	Dopamine D3 receptor antagonists having a morpholine moiety
MX388518B (es)	2016-07-20	2025-03-19	Novartis Ag	Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2.
WO2019110703A1 (fr) *	2017-12-08	2019-06-13	Boehringer Ingelheim International Gmbh	Dérivés d'imidazopyridine et leur utilisation en tant que médicament
CA3136151A1 (fr) *	2019-04-12	2020-10-15	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Composes agonistes du recepteur d3; procedes de preparation; intermediaires de ceux-ci; et leurs procedes d'utilisation
JP7717065B2 (ja)	2019-11-22	2025-08-01	インサイトコーポレーション	Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
WO2021257532A1 (fr)	2020-06-16	2021-12-23	Incyte Corporation	Inhibiteurs d'alk2 pour le traitement de l'anémie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5077290A (en) *	1990-10-11	1991-12-31	Merck & Co., Inc.	Morpholine derivatives compositions and use
GB0130219D0 (en) *	2001-12-18	2002-02-06	Pfizer Ltd	Compounds for the treatment of sexual dysfunction
OA13014A (en) *	2002-12-10	2006-11-10	Pfizer	Morpholine derivatives for use as dopamine agonists in the treatment of i.a sexual dysfunction.

2005
- 2005-05-17 AU AU2005247699A patent/AU2005247699A1/en not_active Abandoned
- 2005-05-17 MX MXPA06013786A patent/MXPA06013786A/es not_active Application Discontinuation
- 2005-05-17 BR BRPI0511571-0A patent/BRPI0511571A/pt not_active Application Discontinuation
- 2005-05-17 AP AP2006003824A patent/AP2006003824A0/xx unknown
- 2005-05-17 EP EP05747191A patent/EP1758862A1/fr not_active Withdrawn
- 2005-05-17 JP JP2007514200A patent/JP4198183B2/ja not_active Expired - Fee Related
- 2005-05-17 WO PCT/IB2005/001554 patent/WO2005115985A1/fr not_active Ceased
- 2005-05-17 EA EA200601982A patent/EA200601982A1/ru unknown
- 2005-05-17 CA CA002567935A patent/CA2567935C/fr not_active Expired - Fee Related
- 2005-05-24 GT GT200500125A patent/GT200500125A/es unknown
- 2005-05-25 PE PE2005000583A patent/PE20060366A1/es not_active Application Discontinuation
- 2005-05-26 PA PA20058635101A patent/PA8635101A1/es unknown
- 2005-05-26 NL NL1029139A patent/NL1029139C2/nl not_active IP Right Cessation
- 2005-05-26 AR ARP050102169A patent/AR049548A1/es unknown
- 2005-05-26 TW TW094117274A patent/TW200609216A/zh unknown
- 2005-05-26 UY UY28925A patent/UY28925A1/es not_active Application Discontinuation
- 2005-05-27 SV SV2005002129A patent/SV2005002129A/es not_active Application Discontinuation
2006
- 2006-11-15 IL IL179314A patent/IL179314A0/en unknown
- 2006-11-20 NO NO20065326A patent/NO20065326L/no unknown
- 2006-11-27 MA MA29488A patent/MA28607B1/fr unknown
- 2006-11-27 EC EC2006007029A patent/ECSP067029A/es unknown

Also Published As

Publication number	Publication date
NL1029139A1 (nl)	2005-11-30
SV2005002129A (es)	2005-12-13
MXPA06013786A (es)	2007-01-25
NL1029139C2 (nl)	2006-06-19
BRPI0511571A (pt)	2008-01-02
CA2567935C (fr)	2009-10-27
TW200609216A (en)	2006-03-16
UY28925A1 (es)	2005-12-30
ECSP067029A (es)	2006-12-29
PA8635101A1 (es)	2006-05-16
EP1758862A1 (fr)	2007-03-07
NO20065326L (no)	2006-12-19
AR049548A1 (es)	2006-08-16
IL179314A0 (en)	2007-03-08
MA28607B1 (fr)	2007-05-02
JP2008500331A (ja)	2008-01-10
EA200601982A1 (ru)	2007-04-27
GT200500125A (es)	2006-01-10
AU2005247699A1 (en)	2005-12-08
WO2005115985A1 (fr)	2005-12-08
AP2006003824A0 (en)	2006-12-31
JP4198183B2 (ja)	2008-12-17
CA2567935A1 (fr)	2005-12-08

Legal Events

Date	Code	Title	Description
2008-12-12	FD	Application declared void or lapsed

Publication	Publication Date	Title
PE20070833A1 (es)	2007-08-27	Compuestos de pirimidinil benzotiofeno
MY133385A (en)	2007-11-30	Benzazoles: benzoxazoles, benzthiazole and benzimidazole derivatives
PE20121157A1 (es)	2012-09-14	Compuestos heterociclicos como inhibidores de proteasas serinas
MY142807A (en)	2011-01-14	Benzimidazole derivative and use thereof.
PE20070136A1 (es)	2007-03-08	COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20091843A1 (es)	2010-01-07	Inhibidores de catepsina c
PE20061353A1 (es)	2006-12-29	Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
AR004002A1 (es)	1998-09-30	Composicion util especialmente para el tratamiento y la proteccion de los animales domesticos infestados o susceptibles de ser infestados por parasitos
PE20080768A1 (es)	2008-06-14	Compuestos de isoindolina 5-sustituidos
PE20100562A1 (es)	2010-08-20	Derivados policiclicos de indazol como inhibidores de erk
PE20060937A1 (es)	2006-10-19	Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20080318A1 (es)	2008-04-10	Derivados de diceto-piperazina y piperidina como agentes antivirales
PE20050072A1 (es)	2005-03-01	Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
PE20081836A1 (es)	2009-03-14	Derivados de piperidina como inhibidores de la sintasa de acido graso
PE20060241A1 (es)	2006-04-01	2-quinolil-oxazoles sustituidos como inhibidores de pde4
PE20121506A1 (es)	2012-11-26	Compuestos triazolopiridinas como inhibidores de c-met
PE20130385A1 (es)	2013-03-30	Derivados del acido naft-2-ilacetico para tratar el sida
PE20090290A1 (es)	2009-04-09	Derivados de pirrolopiridina como inhibidores de bace
PE20090601A1 (es)	2009-06-12	Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
WO2008012733A3 (fr)	2008-07-10	Méthode et composition pour mise en forme durable de la chevelure
PE20120691A1 (es)	2012-06-08	Derivados de n1-sulfonil-5-fluoropirimidinona
PE20150041A1 (es)	2015-01-28	Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
PE20060691A1 (es)	2006-09-06	Serinamidas sustituidas por benzoilo
PE20060366A1 (es)	2006-05-15	Derivados de aminopiridina como agonistas de dopamina
PE20080608A1 (es)	2008-08-01	Compuestos quimicos